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Rethinking the development of Ebola treatments 
In response to the current outbreak, the international 
community has endorsed the clinical use of unregistered 
treatments for Ebola.1 Even with this accelerated 
pathway to in-human testing and use, radically novel 
approaches to drug development will be needed to 
improve the likelihood that a treatment is realised. 
Bypassing steps in development does not alter the 
probability of success, and historical patterns in drug 
development suggest that there is a slim probability 
of success with the current portfolio of potential 
Ebola treatments (all of which are were in preclinical 
development prior to the outbreak).
First, preclinical research in drug development can 
suﬀ er from a lack of replicability, which contributes to 
high development failure rates.2 Second, if preclinical 
develop ment is successful, the likelihood of successful 
regulatory approval of all investigational drugs reaching 
phase 1 is only 10·4%.3 Third, these patterns and low 
rates are based on therapeutic areas with: (a) robust 
preclinical and clinical data collected (often) over 
decades from hundreds to thousands of research and 
development activities spanning the globe, and (b) 
socially and politically acceptable clinical development 
programmes spanning large populations, mainly in 
resource-wealthy settings with strong clinical trial 
infrastructure. Ebola stands in stark contrast to such 
therapeutic areas; thus, one could expect that the 
likelihood of successful regulatory approval for an Ebola 
treatment would be lower than these estimates.
Repurposing (use of approved drugs for new 
indications) or repositioning (use of drugs whose develop-
ment was not continued for new indications) of existing 
drugs has been put forward as a method to overcome 
some of these issues.4 Indeed, drug repositioning and 
repurposing could lead to higher rates of success, with 
lower costs of development, in a faster timeframe 
than de novo discovery approaches.5 However, these 
potential advantages are far from certain. Furthermore, 
drug repurposing/repositioning in and of itself does not 
remove the need for certain preclinical studies and clinical 
trials. Drugs still need to be validated and studied in the 
indications for which they are proposed.
In silico approaches might hold a key to overcoming 
some of these obstacles. Use of bioinformatics-based 
high-end computing to simulate drug–disease biological 
processes provides the ability to bypass time-consuming 
and costly in vitro and in vivo studies and increase 
the probability of success of clinical trials.6 For Ebola 
treatments, in silico approaches might oﬀ er two speciﬁ c 
means to improve the current process and help address 
some of the critical preclinical and clinical concerns 
raised at the WHO meeting of international experts to 
discuss Ebola thera peutics on Sept 5.7 First, the number 
of preclinical compounds already containing clinical data 
for other therapeutic indications could be considerably 
increased. Although traditional repositioning methods 
using in vitro screening have led to initial discoveries 
for Ebola,8 computational screening could provide the 
needed eﬃ  ciency to identify candidates more rapidly 
and accurately than de novo discovery methods. 
Second, virtual clinical trials could alleviate some of 
the logistical and ethical issues surrounding the clinical 
use of unregistered Ebola treatments, including the 
balance between generating safety data and the need 
to introduce treatments as soon as possible.9 This 
method would permit non-interventional assessments 
of pharmacokinetic-pharmacodynamic parameters and 
allow precise and eﬃ  cient clinical trial design10 (the latter 
being particularly important because the epidemiology 
and infrequent emergence of Ebola often provides a 
narrow window of opportunity and limited population 
size to assess an intervention). There is at least one caveat, 
though. In silico approaches are dependent on drug 
and disease process data. Therapeutic Ebola research is 
heavily funded by the US government under the auspices 
of threats to national security,11 and international 
activities are limited to a few research groups. To allow 
for greater participation of researchers globally, real-time 
accessibility of crucial data is necessary.7
In silico methods are still in development and rapidly 
evolving, but have been successful in identifying 
potential candidates for various diseases and the risk 
of using such methods are very low. Their ability to 
aﬀ ect, at scale, drug development processes, costs, and 
timelines is unknown but likely to be considerable given 
the private sector’s strong interest and investment in 
this area. Equally likely is that these approaches will be 
able to aﬀ ect a wide range of diseases. Although these 
approaches are currently directed towards diseases 
with clear revenue streams (eg, inﬂ ammatory bowel 
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disease and cancer), such approaches could be used for 
unproﬁ table diseases that aﬀ ect the most underserved 
populations of the world. 
The inequities already posed by a disease of poverty such as 
Ebola become further exacerbated when novel technologies 
are used ﬁ rst to explore diseases that are viable commercial 
opportunities. This does not have to be the pattern moving 
forward, and Ebola might provide the opportunity to apply 
new technological approaches to drug development (such 
as in silico methods) for traditional “market failure” diseases. 
If the global community is truly committed to rapidly 
developing a new drug for Ebola, multiple novel approaches, 
methods, and technologies will need to be used to beat the 
inherent hurdles of drug development.
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